Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Disintegrin and metalloproteinase domain-containing protein 18 (ADAM18) is a membrane-anchored, sperm surface protein that belongs to the ADAM (a disintegrin and metalloproteinase) family, which are structurally related to snake venom disintegrins and regulate cell–cell and cell–matrix interactions[2][5][7]. Unlike many ADAM family members, ADAM18 lacks critical residues in the catalytic site and is considered a non-catalytic or proteolytically inactive metalloproteinase[1][7]. Its biological role appears to be primarily in the reproductive system—specifically, sperm function and possibly spermatogenesis and fertilization—through mediating cell adhesion rather than proteolysis[2][7]. There is no current evidence of ADAM18 serving as a drug target or biomarker in disease, and its clinical significance is limited mainly to potential roles in reproductive biology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Disintegrin and metalloproteinase domain-containing protein 18 (ADAM18).